Previous 10 | Next 10 |
home / stock / invvy / invvy news
2023-07-27 06:00:37 ET Indivior PLC ADR press release ( OTCPK:INVVY ): Q2 Non-GAAP EPS of $0.39. Revenue of $276M (+24.9% Y/Y). For further details see: Indivior PLC ADR Non-GAAP EPS of $0.39, revenue of $276M
Indivior Announces Q2/H1 2023 Financial Results PR Newswire SLOUGH, United Kingdom , and RICHMOND, Va. , July 27, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending June 30, 2023 . The earnings...
Indivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence PR Newswire RICHMOND, Va. , June 14, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced the acceptanc...
Indivior to Commence Trading on Nasdaq PR Newswire Company to Ring Opening Bell June 14 to Bring Awareness to Addiction Treatment; Company Will Maintain Premium Listing on London Stock Exchange RICHMOND, Va. , June 12, 2023 /PRNewswire/ -- Indiv...
2023-06-02 13:24:58 ET Indivior PLC ( OTCPK:INVVY ) announced Friday that it would pay $102.5M to settle a multistate litigation related to allegations that the company used illegal means to shield its opioid addiction treatment Suboxone from generic competition. The agreement betwe...
Indivior Reaches Agreement with States' Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation Claims PR Newswire RICHMOND, Va. , June 2, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV), a leading addiction treatment company, anno...
Indivior To Participate In Upcoming Investor Conferences PR Newswire SLOUGH, England and RICHMOND, Va. , May 25, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced that it will participate in the following investor events: Jeffe...
Indivior PLC Form 20-F Registration Statement for Additional US Listing Now Available; Trading on NASDAQ Expected to Commence on June 12th PR Newswire RICHMOND, Va. , May 23, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced that its registration stat...
Indivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl PR Newswire In the 12-month period ending in December 2022 , over 79,000 people in the U...
2023-04-29 07:56:06 ET Indivior PLC (INVVY) Q1 2023 Earnings Conference Call April 27, 2023 08:00 AM ET Company Participants Jason Thompson - Vice President of Investor Relations Mark Crossley - Chief Executive Officer Christian Heidbreder - Chief Scientific Offi...
News, Short Squeeze, Breakout and More Instantly...
Indivior PLC ADR Company Name:
INVVY Stock Symbol:
OTCMKTS Market:
Indivior Announces Q1 2024 Financial Results PR Newswire SLOUGH, United Kingdom and RICHMOND, Va. , April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024 . The earnings re...
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone PR Newswire This head-to-head pharmacodynamic study in healthy volunteers...
Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation PR Newswire RICHMOND, Va. , Feb. 29, 2024 /PRNewswire/ -- Indivior PLC (LSE: I...